Jefferies Financial Group Inc. acquired a new position in Climb Bio, Inc. (NASDAQ:CLYM – Free Report) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 290,850 shares of the company’s stock, valued at approximately $3,336,000. Jefferies Financial Group Inc. owned approximately 0.51% of Climb Bio at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in CLYM. Dimensional Fund Advisors LP purchased a new stake in shares of Climb Bio in the 1st quarter worth about $715,000. BlackRock Inc. bought a new position in shares of Climb Bio in the 2nd quarter worth about $30,708,000. Bank of New York Mellon Corp purchased a new position in Climb Bio during the 2nd quarter valued at about $1,613,000. Braidwell LP lifted its position in Climb Bio by 102.6% during the 2nd quarter. Braidwell LP now owns 3,099,027 shares of the company’s stock valued at $40,411,000 after acquiring an additional 1,569,352 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new position in Climb Bio during the 2nd quarter valued at about $2,148,000. Hedge funds and other institutional investors own 69.76% of the company’s stock.
Climb Bio Stock Down 11.3%
Shares of CLYM opened at $10.87 on Friday. Climb Bio, Inc. has a twelve month low of $1.63 and a twelve month high of $18.33. The company has a market capitalization of $638.50 million, a P/E ratio of -13.26 and a beta of 0.01. The firm has a 50 day moving average of $11.66 and a 200 day moving average of $10.60.
Insider Buying and Selling
In other Climb Bio news, Director Stephen Thomas sold 100,000 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $13.67, for a total value of $1,367,000.00. Following the completion of the transaction, the director owned 467,969 shares of the company’s stock, valued at approximately $6,397,136.23. The trade was a 17.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 2.60% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on CLYM shares. Piper Sandler restated an “overweight” rating on shares of Climb Bio in a report on Tuesday, October 27th. Deutsche Bank started coverage on shares of Climb Bio in a research note on Tuesday, October 20th. They set a “buy” rating and a $28.00 target price for the company. Oppenheimer boosted their price target on Climb Bio from $18.00 to $25.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 8th. Wedbush boosted their price target on Climb Bio from $25.00 to $27.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th. Finally, Robert W. Baird raised their price objective on Climb Bio from $21.00 to $25.00 and gave the company an “outperform” rating in a research report on Thursday, September 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $28.14.
View Our Latest Report on CLYM
Climb Bio Profile
Climb Bio is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases, with a focus on conditions involving B cells and antibody production. Its lead candidate, budoprutug, is an antibody designed to engage CD19 and FcγRIIb to inhibit B-cell activity. The company is evaluating the candidate in clinical studies for immune-mediated diseases, including immune thrombocytopenia and membranous nephropathy. Climb Bio is also developing CLYM-116, an antibody targeting APRIL, a protein involved in B-cell and antibody activity.
Read More
- Five stocks we like better than Climb Bio
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
